Latest news with #AgilonHealth
Yahoo
6 days ago
- Business
- Yahoo
Here's What Key Metrics Tell Us About Agilon (AGL) Q2 Earnings
Agilon Health (AGL) reported $1.39 billion in revenue for the quarter ended June 2025, representing a year-over-year decline of 5.9%. EPS of -$0.25 for the same period compares to -$0.07 a year ago. The reported revenue represents a surprise of -4.98% over the Zacks Consensus Estimate of $1.47 billion. With the consensus EPS estimate being -$0.11, the EPS surprise was -127.27%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Avg. Medicare Advantage Members: 498,000 compared to the 493,100 average estimate based on two analysts. Revenues- Other operating: $2.94 million versus $3.16 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -7.4% change. Revenues- Medical services: $1.39 billion compared to the $1.46 billion average estimate based on five analysts. The reported number represents a change of -5.9% year over year. View all Key Company Metrics for Agilon here>>> Shares of Agilon have returned -30% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilon Health, Inc. (AGL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
Agilon Health (AGL) Reports Q2 Loss, Misses Revenue Estimates
Agilon Health (AGL) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -127.27%. A quarter ago, it was expected that this senior-focused health care company would post a loss of $0.01 per share when it actually produced break-even earnings, delivering a surprise of +100%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Agilon, which belongs to the Zacks Medical Services industry, posted revenues of $1.39 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.98%. This compares to year-ago revenues of $1.48 billion. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Agilon shares have lost about 10.5% since the beginning of the year versus the S&P 500's gain of 6.1%. What's Next for Agilon? While Agilon has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Agilon was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $1.46 billion in revenues for the coming quarter and -$0.28 on $5.95 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Progyny (PGNY), another stock in the same industry, has yet to report results for the quarter ended June 2025. The results are expected to be released on August 7. This provider of fertility and family building benefits is expected to post quarterly earnings of $0.44 per share in its upcoming report, which represents a year-over-year change of +2.3%. The consensus EPS estimate for the quarter has been revised 4.1% lower over the last 30 days to the current level. Progyny's revenues are expected to be $322.5 million, up 6.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Agilon Health, Inc. (AGL) : Free Stock Analysis Report Progyny, Inc. (PGNY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
04-08-2025
- Business
- Yahoo
agilon health (AGL) Q2 Earnings: What To Expect
Healthcare services company Agilon Health (NYSE:AGL) will be announcing earnings results this Tuesday after the bell. Here's what to look for. agilon health beat analysts' revenue expectations by 1.8% last quarter, reporting revenues of $1.53 billion, down 4.5% year on year. It was a slower quarter for the company, with a significant miss of analysts' EPS estimates and EBITDA guidance for next quarter missing analysts' expectations significantly. It lost -36,000 customers and ended up with a total of 491,000. Is agilon health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting agilon health's revenue to be flat year on year at $1.47 billion, slowing from the 38.7% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.11 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. agilon health has missed Wall Street's revenue estimates five times over the last two years. Looking at agilon health's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 4.5%, meeting analysts' expectations, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. Select Medical traded down 15.1% following the results while CVS Health's stock price was unchanged. Read our full analysis of Select Medical's results here and CVS Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. agilon health is down 25.8% during the same time and is heading into earnings with an average analyst price target of $3.59 (compared to the current share price of $1.73). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
17-07-2025
- Business
- Business Insider
Agilon Health (AGL) Receives a Buy from Bernstein
Bernstein analyst Lance Wilkes maintained a Buy rating on Agilon Health yesterday and set a price target of $4.00. The company's shares closed yesterday at $2.16. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Centene, and Humana. According to TipRanks, Wilkes has an average return of -4.9% and a 37.50% success rate on recommended stocks. Currently, the analyst consensus on Agilon Health is a Hold with an average price target of $4.55.
Business Insider
09-07-2025
- Business
- Business Insider
Bernstein Sticks to Its Buy Rating for Agilon Health (AGL)
Bernstein analyst Lance Wilkes maintained a Buy rating on Agilon Health yesterday and set a price target of $7.50. The company's shares closed yesterday at $2.39. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Wilkes is an analyst with an average return of -2.7% and a 43.42% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as UnitedHealth, Centene, and Agilon Health. The word on The Street in general, suggests a Hold analyst consensus rating for Agilon Health with a $4.60 average price target. Based on Agilon Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.53 billion and a net profit of $12.11 million. In comparison, last year the company earned a revenue of $1.6 billion and had a net profit of $2.7 million
